News for Healthier Living

SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

September 1, 2024


September 17 2024

September 16 2024

September 15 2024

September 14 2024

September 13 2024

September 12 2024

September 11 2024

September 10 2024

September 9 2024

September 8 2024

September 7 2024

September 6 2024

September 5 2024

September 4 2024

September 3 2024